FrancophonIA/ELRC3.0 huggingface dataset:
English: Muscle rigidity Muscle spasms Muscle twitching Muscle tightness Myalgia
Estonian: Lihasrigiidsus Lihasspasmid Lihastõmblused Lihasepingsus Müalgia
English: Injection site induration Fatigue
Estonian: Süstekoha valu Süstekoha induratsioon Väsimus
English: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Each vial contains 300 mg aripiprazole.
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti Iga viaal sisaldab 300 mg aripiprasooli.
English: Abilify Maintena is a powder and solvent for prolonged-release suspension for injection.
Estonian: Abilify Maintena on toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti.
English: • unusual movements (especially of the face or tongue) and reduced level of consciousness.
Estonian: • kiire südametegevus, agiteeritus/agressiivsus, kõneprobleemid; • ebaharilikud liigutused (eriti nägu või keel) ja teadvuse häired.
English: Visually confirm that the needle is fully engaged into the needle protection sheath, and discard.
Estonian: Veenduge visuaalselt, et nõel on tervenisti nõelakaitses ja kõrvaldage kasutusest.
English: No cases of overdose associated with adverse reactions were reported in clinical studies with Abilify Maintena.
Estonian: Abilify Maintena kliinilistes uuringutes ei ole teatatud kõrvaltoimetega seotud üleannustamise juhtudest.
English: Alkaline phosphatase increased
Estonian: Alkaalse fosfataasi aktiivsuse tõus
English: Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with aripiprazole.
Estonian: Atüüpiliste antipsühhootikumidega, sealhulgas aripiprasooliga ravitud patsientidel on registreeritud hüperglükeemiat, mõnedel juhtudel tõsist, millega on kaasnenud ketoatsidoos, hüperosmolaarne kooma või surm.
English: • pain at the injection site, hardening of the skin at the injection site
Estonian: • valu süstekohal, naha kõvenemine süstekohal;
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton - Single pack 400 mg
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Väliskarp - üksikpakend 400 mg
English: Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Each vial contains 400 mg aripiprazole.
Estonian: Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti Iga viaal sisaldab 400 mg aripiprasooli.
English: Mean baseline (SD)
Estonian: Keskmine algväärtus (SD)
English: • dizziness when getting up from a lying or sitting position due to a drop in blood pressure
Estonian: • pearinglus vererõhu languse tõttu lamavast või istuvast asendist püsti tõustes;
English: If the injection is not performed immediately after reconstitution, the syringe can be kept below 25 °C for up to 2 hours.
Estonian: Kui süstimine ei toimu kohe pärast valmistamist, võib süstlit hoida temperatuuril alla 25 °C kuni 2 tundi.
English: Dispose of the vials, adapter, needles, and syringe appropriately after injection.
Estonian: Hävitage ohutult viaal, adapter, süstal, nõelad, kasutamata suspensioon ja süstevesi.
English: Gently press the sheath against a flat surface until the needle is firmly engaged in the needle protection sheath.
Estonian: Vajutage ümbris kergelt vastu kõva pinda, kuni nõel on kindlalt nõelakaitses.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton - Single pack 300 mg
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Väliskarp - üksikpakend 300 mg
English: 51 mm (2 inch) 21 gauge c) Slowly inject the recommended volume as a single intramuscular injection into the gluteal or deltoid muscle.
Estonian: c) Süstige aeglaselt soovitatav kogus ühekordse intramuskulaarse süstena tuhara- või deltalihasesse.
English: • sensitivity to light
Estonian: • valgustundlikkus;
English: Carmellose sodium
Estonian: Naatriumkarmelloos Mannitool
English: • heartburn
Estonian: • pearinglus;
English: - higher amounts of glycosylated haemoglobin
Estonian: - glükosüülitud hemoglobiini suuremaid koguseid;
English: One pre-filled syringe containing powder in the front chamber and solvent in the rear chamber.
Estonian: Üks süstel, mis sisaldab pulbrit esimeses kambris ja lahustit tagumises kambris Kolm hüpodermilist turvanõela
English: In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole.
Estonian: Aeg-ajalt on kuni üks aasta väldanud kliinilistes uuringutes teatatud düskineesia ilmnemisest aripiprasoolravi ajal.
English: Nephrolithiasis Glycosuria
Estonian: Nefrolitiaas Glükosuuria
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton (without blue box) - component of multipack 400 mg
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp (ilma sinise kastita) - multipakendi osa 400 mg
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton (without blue box) - component of multipack 300 mg
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp (ilma sinise kastita) - multipakendi osa 300 mg
English: • low levels of white blood cells
Estonian: • valgete vereliblede madal tase;
English: Each vial contains 400 mg aripiprazole.
Estonian: Üks viaal sisaldab 400 mg aripiprasooli.
English: Sluggishness
Estonian: Kehakaal
English: Concomitant oral aripiprazole should be restarted for 14 days with next administered injection.
Estonian: Samaaegselt järgmise süstega peab uuesti alustama suukaudse aripiprasooli 14-päevast kuuri.
English: Each vial contains 300 mg aripiprazole.
Estonian: Üks viaal sisaldab 300 mg aripiprasooli.
English: During the double-blind, controlled phases of the two long-term trials, injection site reactions were observed; those seen were generally mild to moderate in severity, and resolved over time.
Estonian: Kahe pikaajalise uuringu topeltpimedas kontrollitud faasis täheldati süstekoha reaktsioone.
English: Blood bilirubin increased Aspartate aminotransferase increased
Estonian: Alaniinaminotransferaasi aktiivsuse tõus Gammaglutamüültransferaa si aktiivsuse tõus Vere bilirubiinisisalduse tõus
English: • high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite and feeling weak) or family history of diabetes
Estonian: • kõrge veresuhkru tase (mida iseloomustavad sümptomid nagu liigne janu, uriini suur hulk,
English: • distortion of the senses of taste and smell
Estonian: • maitse- ja lõhnatundlikkuse häired;
English: The incidence of weight loss of ≥ 7 % from baseline to last visit was 10.2 % for Abilify Maintena and 4.5 % for oral aripiprazole tablets 10-30 mg. During the Doubleblind, Placebo-controlled Phase of the 52-week long-term trial, the incidence of weight gain of ≥ 7 % from baseline to last visit was 6.4 % for Abilify Maintena and 5.2 % for placebo.
Estonian: 52-nädalase pikaajalise uuringu topeltpimedas platseebokontrolliga faasis oli kehakaalu ≥ 7 % suurenemise esinemissagedus algmomendist kuni viimase visiidini 6,4 % Abilify Maintena ja 5,2 % platseebo puhul.
English: Pancreatitis Dysphagia
Estonian: Süstitav kogus
English: Erectile dysfunction
Estonian: Ekstrapüramidaalhäired
English: strong impulse to gamble excessively despite serious personal or family consequences altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive uncontrollable excessive shopping binge eating (eating large amounts of food in a short time period) or compulsive eating
Estonian: muutunud või suurenenud seksuaalne huvi ja käitumine, mis tekitab muret teile või teistele - nt suurenenud suguiha;
English: • excessive sweating
Estonian: • liigne higistamine;
English: • diabetes mellitus
Estonian: deltalihas tuharalihas
English: Abilify Maintena 300 mg injection aripiprazole
Estonian: Abilify Maintena 300 mg süstevedelik aripiprasool i.m.
English: • chest pain
Estonian: • valu rinnus;
English: If you miss an injection of Abilify Maintena
Estonian: Kui te unustate Abilify Maintena süstimise
English: • loss of strength
Estonian: • jõuetus;
English: • stomach discomfort
Estonian: • ebamugavustunne kõhus;
English: Abilify Maintena 400 mg injection aripiprazole
Estonian: Abilify Maintena 400 mg süstevedelik aripiprasool i.m.
English: Blood cholesterol decreased Blood triglycerides decreased
Estonian: Vere triglütseriidide sisalduse vähenemine
English: An elevated risk of acute dystonia is observed in males and younger age groups.
Estonian: Meestel ja nooremasse vanusegruppi kuuluvatel patsientidel on suurem risk ägeda düstoonia tekkeks.
English: • difficulty in passing urine
Estonian: • urineerimisraskused;
English: Absorption of aripiprazole from the IM depot formulation was complete relative to the IM standard (immediate-release) formulation.
Estonian: Aripiprasooli imendumine intramuskulaarselt manustatavast (i.m) depoovormist oli täielik võrreldes i.m.
English: If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued (see section 4.8).
Estonian: Kõikide antipsühhootikumide, sealhulgas aripiprasooli manustamine tuleb lõpetada, kui patsiendil ilmnevad võimalikud MNS-i tunnused või sümptomid või täiendavate MNS-i kliiniliste tunnusteta ebaselge etioloogiaga kõrge palavik (vt lõik 4.8).
English: Pain in extremity Arthralgia
Estonian: Valu jäsemetes Artralgia
English: Shake the syringe vigorously for at least 20 seconds to re-suspend prior to injection if the syringe has been left for more than 15 minutes.
Estonian: Kui süstel on olnud kasutamata rohkem kui 15 minutit, loksutage süstlit enne süstimist tugevasti vähemalt 20 sekundit, et lahus uuesti suspendeerida.
English: Common
Estonian: Normkaalus
English: • blurred vision
Estonian: • sage roojamine;
English: Risk factors that may predispose patients to severe complications include obesity and family history of diabetes.
Estonian: Ülekaalulisus ja diabeedi esinemine perekonnas on riskifaktoriteks, mis võivad soodustada patsiendil tõsiste tüsistuste teket.
English: Contents of the pack and other information
Estonian: Kuidas Abilify Maintena't säilitada Pakendi sisu ja muu teave
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer label (with blue box) - Multipack 300 mg
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Väline etikett (sinise kastiga) - multipakend 300 mg
English: Gluteal injections should be alternated between the two gluteal muscles.
Estonian: Tuharalihasesse süstimiseks kasutage kahte tuharalihast vaheldumisi.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer label (with blue box) - Multipack 400 mg
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Väline etikett (sinise kastiga) - multipakend 400 mg
English: Abilify Maintena 400 mg powder for prolonged-release injection aripiprazole
Estonian: Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti aripiprasool
English: *If there's resistance or difficulty expelling air, check that plunger rod is rotated to a complete stop.
Estonian: *Kui õhu väljalaskmisega on raskusi või tunnete vastupanu,
English: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti süstlis Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti süstlis
English: Abilify Maintena 300 mg powder for prolonged-release injection aripiprazole
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti aripiprasool
English: Hepatic impairment
Estonian: Pankreatiit Düsfaagia
English: The incidences of the ADRs associated with aripiprazole therapy are tabulated below.
Estonian: Aripiprasoolraviga seotud kõrvaltoimete esinemissagedused on toodud allolevas tabelis.
English: A number of symptoms of dystonia are then listed, including spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.
Estonian: Teiste ravimvormide puhul nimetatakse ravimi omaduste kokkuvõtte lõigus 4.8, et düstoonia on selle ravimi klassiefekt, misjärel on toodud düstoonia mitmed sümptomid, sealhulgas kaelalihaste spasm, vahel progresseeruv kõri survetunne, neelamisraskus, hingamisraskus ja/või keele protrusioon.
English: Hypersensitivity
Estonian: Hüperprolaktineemia
English: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe aripiprazole
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti süstlis Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti süstlis aripiprasool
English: Dry mouth Gastrooesophageal reflux disease
Estonian: Gastroösofageaalne reflukshaigus Düspepsia
English: Syncope
Estonian: Multipakend
English: Renal impairment
Estonian: Rindade hellus
English: Each pre-filled syringe contains 300 mg aripiprazole.
Estonian: Iga süstel sisaldab 300 mg aripiprasooli.
English: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti
English: Blood and lymphatic system disorders
Estonian: Teadmata lümfisüsteemi häired
English: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection aripiprazole
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti aripiprasool
English: Each pre-filled syringe contains 400 mg aripiprazole.
Estonian: Iga süstel sisaldab 400 mg aripiprasooli.
English: The recommended starting and maintenance dose of Abilify Maintena is 400 mg. Titration of the dose of this medicinal product is not required.
Estonian: Abilify Maintena soovitatav alg- ja säilitusannus on 400 mg.
English: - One 38 mm (1.5 inch) 22 gauge hypodermic safety needle with needle protection device.
Estonian: Ülekaalulistel patsientidel tuleb kasutada 38 mm 22 G hüpodermilist turvanõela.
English: • suicide attempt and suicide
Estonian: • suitsiidikatse ja suitsiid;
English: • chest discomfort
Estonian: • rahutustunne;
English: - One 25 mm (1 inch) 23 gauge hypodermic safety needle with needle protection device.
Estonian: Deltalihasesse manustamiseks soovitatav nõel on 25 mm 23 G hüpodermiline turvanõel.
English: Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe aripiprazole
Estonian: Abilify Maintena 400 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti süstlis aripiprasool
English: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe aripiprazole
Estonian: Abilify Maintena 300 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti süstlis aripiprasool
English: Mean baseline (SD) Mean change (SD) P-value
Estonian: Keskmine muutus (SD)
English: • sluggishness
Estonian: • kõhukinnisus;
English: Solvent
Estonian: Annus
English: • dizziness
Estonian: • meelepetted;
English: Jaundice
Estonian: Kehatüüp
English: Missed doses
Estonian: Lahusti Süstevesi
English: Abilify Maintena comes as a pre-filled syringe.
Estonian: Abilify Maintena lahusti Süstevesi
English: When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient.
Estonian: Loodetav kasu peab ületama võimaliku ohu patsiendile, kui kaalutakse ketokonasooli või teiste tugevate CYP3A4 inhibiitorite samaaegset manustamist koos aripiprasooliga.
English: The recommended needle for gluteal administration is a 38 mm (1.5 inch), 22 gauge hypodermic safety needle; for obese patients (Body mass index > 28 kg/m2), a 51 mm (2 inch), 21 gauge hypodermic safety needle should be used.
Estonian: Ülekaalulistel patsientidel (kehamassiindeks > 28 kg/m2) peab kasutama 51 mm 21 G hüpodermilist turvanõela.
English: Talk to your doctor about the best way to feed your baby if you are receiving Abilify Maintena.
Estonian: Kui saate Abilify Maintena't, rääkige oma arstiga teie lapse parimast toitmisviisist.
English: Dyskinesia Sedation Somnolence Dizziness Headache
Estonian: Oksendamine Kõhulahtisus Iiveldus
English: Blood glucose increased Blood glucose decreased Glycosylated haemoglobin increased
Estonian: Glükosüleeritud hemoglobiini sisalduse suurenemine
English: - One 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch) 21 gauge hypodermic safety needle with needle protection device.
Estonian: - üks 3 ml luer lock süstal eelkinnitatud 38 mm 21 G hüpodermiline turvanõel nõelakaitsmega; - üks 3 ml ühekordne süstal luer lock otsikuga; - üks viaali adapter; - üks 25 mm 23 G hüpodermiline turvanõel nõelakaitsmega; - üks 38 mm 22 G hüpodermiline turvanõel nõelakaitsmega; - üks 51 mm 21 G hüpodermiline turvanõel nõelakaitsmega; - Süstla ja nõela juhendid.
English: Engage the needle safety device as described in Step 2 e).
Estonian: Käituge nõelakaitsmega nagu kirjeldatud 2. sammu punktis e. Pärast süstimist hävitage viaalid, adapter, nõelad ja süstal.
English: Blood prolactin decreased Hyperprolactinaemia
Estonian: Prolaktiinisisalduse langus veres
English: Mannitol
Estonian: Minestus
English: Mekinist (trametinib)
Estonian: Mekinist (trametiniib)
English: Mekinist received a marketing authorisation valid throughout the EU on 30 June 2014.
Estonian: Mekinist on saanud müügiloa, mis kehtib kogu ELis, 30. juunil 2014.
English: Further information on Mekinist can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Mekinisti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Mekinist?
Estonian: Mis meetmed võetakse, et tagada Mekinisti ohutu ja efektiivne kasutamine?
English: Mekinist is available as tablets (0.5 and 2 mg).
Estonian: Mekinisti turustatakse tablettidena (0,5 mg ja 2 mg).
English: Other information about Mekinist
Estonian: Muu teave Mekinisti kohta
English: The dose of Mekinist is 2 mg once a day taken on an empty stomach (at least 1 hour before or 2 hours after a meal) and at around the same time every day.
Estonian: Mekinisti manustatakse annuses 2 mg kord ööpäevas tühja kõhuga (vähemalt 1 tund enne või 2 tundi pärast söömist) ja iga päev ligikaudu samal kellaajal.
English: As for all medicines, data on the use of Mekinist are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Mekinisti kasutamise kohta pidevat järelevalvet.
English: Mekinist's side effects were considered acceptable and manageable with appropriate measures.
Estonian: Kõrvalnähte peeti vastuvõetavateks ja sobivate meetmetega hallatavateks.
English: Treatment with Mekinist must be started and supervised by a doctor experienced in the use of cancer medicines.
Estonian: Ravi Mekinistiga peab alustama ja jälgima vähiravimite kasutamises kogenud arst.
English: What is Mekinist and what is it used for?
Estonian: Mis on Mekinist ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mekinist have been included in the summary of product characteristics and the package leaflet.
Estonian: Mekinisti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Mekinist, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Mekinisti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The European Medicines Agency decided that Mekinist's benefits in cancers that carry the BRAF V600 mutation are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Mekinisti kasulikkus BRAF V600 mutatsiooniga vähivormide korral on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Treatment may need to be interrupted or stopped, or the dose reduced, if certain side effects occur.
Estonian: Teatud kõrvalnähtude tekkimisel võib olla vaja ravi katkestada või lõpetada või annust vähendada.
English: Side effects reported with Mekinist are carefully evaluated and any necessary action taken to protect patients.
Estonian: Mekinisti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: This leads cancers to develop by allowing uncontrolled division of cells.
Estonian: See põhjustab vähi teket, võimaldades kasvajarakkudel piiramatult jaguneda.
English: In an additional study Mekinist did not show any benefit when given to patients who did not respond to previous treatment with another cancer medicine that blocked BRAF.
Estonian: Lisauuringus ei õnnestunud tõendada Mekinisti kasulikkust patsientidel, kellel ei olnud tekkinud ravivastust varasemale ravile muu BRAF-valku blokeeriva vähiravimiga.
English: Mekinist is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) in their genes called 'BRAF V600'.
Estonian: Mekinist on vähiravim, millega ravitakse täiskasvanuid, kelle vähirakkudes on teatav geenimutatsioon (geenimuutus) - BRAF V600.
English: Response to treatment was assessed using body scans and patients' clinical data.
Estonian: Ravivastust hinnati tomograafiauuringutega ja patsiendi kliiniliste andmete põhjal.
English: What are the risks associated with Mekinist?
Estonian: Mis riskid Mekinistiga kaasnevad?
English: The most common side effects with Mekinist (which may affect more than 1 in 5 people) are rash, diarrhoea, tiredness, peripheral oedema (swelling, especially of ankles and feet), nausea and acneiform dermatitis (acne-like inflammation of the skin).
Estonian: Mekinisti kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on lööve, kõhulahtisus, väsimus, perifeerne ödeem (turse, eriti pahkluudel ja jalalabadel), iiveldus ja akneformne dermatiit (aknetaoline nahapõletik).
English: The active substance in Mekinist, trametinib, works by blocking MEK and by preventing its activation by BRAF, thereby slowing down the growth and spread of the cancer.
Estonian: Mekinisti toimeaine trametiniib blokeerib MEK-valgu ja takistab BRAF-valgul seda aktiveerimast, aeglustades nii vähi kasvu ja levikut.
English: When Mekinist is taken in combination with dabrafenib the most common side effects (which may affect more than 1 in 5 people) are fever, tiredness, nausea, chills, headache, diarrhoea, vomiting, joint pain and rash.
Estonian: Mekinisti ja dabrafeniibi kombinatsiooni kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on palavik, väsimus, iiveldus, külmavärinad, peavalu, kõhulahtisus, oksendamine, liigesevalu ja lööve.
English: How is Mekinist used?
Estonian: Kuidas Mekinisti kasutatakse?